Andrew Isaacs
Andrew Isaacs (ENG’81) of Bedminster, N.J., founded the biotech company Interstice Therapeutics, LLC. Andrew has worked in the life science/pharma industry for 30 years, which, he says, has given him “firsthand experience in global product development, launching many products, and assessing thousands of drugs for in/out licensing. Unfortunately, most of the big drug companies are only seeking ‘blockbuster’ drugs that have multibillion-dollar revenue opportunities and are not structured to manage the various revenue contributions from smaller or shorter in-market exclusivity products. So, when ‘new’ drugs are launched, there is an enormous expectation of adoption/uptake that rarely happens, leaving a treatment gap that may be addressed by simple combination therapies. This presents an enormous opportunity to fill this gap that not only meets unmet clinical needs, but is also profitable. Therefore, the first drug target for us is a simple combination cardiology drug that has the potential to address a significant unmet medical need and help prevent thousands of deaths each year.” Contact Andrew at ahi_biomed@yahoo.com.
From the Fall 2018 issue.